STOCKHOLM, Sweden--(BUSINESS WIRE)--Meda AB (STO:MEDAA): Integration of 3M’s pharma division in Europe went faster than forecasted. All non-recurring restructuring costs recognised in Q1 2007. Significantly improved underlying operating profit. The Group’s net sales reached SEK 1,788.1 million (1,316.2). Operating profit, excluding non-recurring items, increased to SEK 434.1 million (1) (225.6)(2).
